Imaging allows a non-invasive assessment of biochemical and biological processes in a living subject. Monitoring, assessing, and characterising novel therapeutics in pre-clinical models is an essential part of drug development.
In this webinar Dr Juliana Maynard, Lead Scientist in Pre-clinical Imaging, and Dr Philippa Hart, Lead Scientist in Mass Spectrometry Imaging, explore available imaging technologies and techniques and explain how they can help at different stages of the drug development process.
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at physicochemical characterisation new and novel approaches to understand the pharmacokinetics of complex drugs.
Juliana Maynard (MDC)
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at physicochemical characterisation new and novel approaches to understand the pharmacokinetics of complex drugs.
Juliana Maynard (MDC)
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the target landscape for Complex Medicine.
Dr Duygu Yilmaz, Medicines Discovery Catapult
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at precision drug delivery with therapeutic microbubbles and the promise that they bring.
Louise Coletta, University of Leeds
Big Data and Genomic Medicine by Corey NislowKnome_Inc
View the webinar at: http://www.knome.com/webinar-big-data-genomic-medicine. This presentation covers an overview of genomic medicine, requirements and challenges of next-generation sequencing, bottlenecks to broader healthcare adoption, and why “we want to sequence everyone.”
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at how you can determine efficacy in vivo.
Jenny Worthington (Axis Bio)
Download Global cancer nanomedicine market outlook 2022KuicK Research
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Methods, Challenges and Future Directions of Radiogenomics-Crimson PublishersCrimsonpublishersCancer
Tissue response to the radiation is a complex pathophysiological process and is an inherited polygenic trait. Aim of the Radiogenomics studies is to discover related genetic variants that confer tumor or nontumor tissue radio sensitivity as the target of radio-sensitizing and/or radio-protective agents and to identify specific genetic markers for prognosis or risk prediction. The methods for radiogenomics studies include candidate gene approaches, genome-wide association studies, Next-Generation Sequencing (NGS), epigenetic study, and other methods. The future direction of radiogenomics should be the development of the polygenic risk scores that are incorporated into end point-specific clinical models/nomograms.
Global cancer nanomedicine market outlook 2022Rajesh Sarma
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview & Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design & Strategy
Cancer Nanomedicine as Diagnostic & Therapeutics Tool
Global Cancer Nanomedicine Market Overview & Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Webinar analyzing complex genomic variants in somatic cancer Lisa Owen
Next generation sequencing (NGS) technologies facilitate the accurate detection of genetic and genomic variants. Yet the process of analyzing and classifying more complex alterations remains challenging.
In this slide deck, which is a companion to the webinar presented on February 21, 2019 and located here (https://www.pieriandx.com/analyzingcomplexgenomicvariants) you’ll learn how to analyze complex genomic alterations, such as gene fusions, splice-site mutations, and co-occurring variants within the context of somatic cancer.
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the target landscape for Complex Medicine.
Dr Duygu Yilmaz, Medicines Discovery Catapult
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at precision drug delivery with therapeutic microbubbles and the promise that they bring.
Louise Coletta, University of Leeds
Big Data and Genomic Medicine by Corey NislowKnome_Inc
View the webinar at: http://www.knome.com/webinar-big-data-genomic-medicine. This presentation covers an overview of genomic medicine, requirements and challenges of next-generation sequencing, bottlenecks to broader healthcare adoption, and why “we want to sequence everyone.”
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at how you can determine efficacy in vivo.
Jenny Worthington (Axis Bio)
Download Global cancer nanomedicine market outlook 2022KuicK Research
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Methods, Challenges and Future Directions of Radiogenomics-Crimson PublishersCrimsonpublishersCancer
Tissue response to the radiation is a complex pathophysiological process and is an inherited polygenic trait. Aim of the Radiogenomics studies is to discover related genetic variants that confer tumor or nontumor tissue radio sensitivity as the target of radio-sensitizing and/or radio-protective agents and to identify specific genetic markers for prognosis or risk prediction. The methods for radiogenomics studies include candidate gene approaches, genome-wide association studies, Next-Generation Sequencing (NGS), epigenetic study, and other methods. The future direction of radiogenomics should be the development of the polygenic risk scores that are incorporated into end point-specific clinical models/nomograms.
Global cancer nanomedicine market outlook 2022Rajesh Sarma
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview & Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design & Strategy
Cancer Nanomedicine as Diagnostic & Therapeutics Tool
Global Cancer Nanomedicine Market Overview & Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Webinar analyzing complex genomic variants in somatic cancer Lisa Owen
Next generation sequencing (NGS) technologies facilitate the accurate detection of genetic and genomic variants. Yet the process of analyzing and classifying more complex alterations remains challenging.
In this slide deck, which is a companion to the webinar presented on February 21, 2019 and located here (https://www.pieriandx.com/analyzingcomplexgenomicvariants) you’ll learn how to analyze complex genomic alterations, such as gene fusions, splice-site mutations, and co-occurring variants within the context of somatic cancer.
Presentation by Dr. Elena Faccenda on the IUPHAR/BPS Guide to Immunopharmacology at the 39° Congresso Nazionale della Società Italiana di Farmacologia in Florence, Nov 2019
Clinical Genomics for Personalized Cancer Medicine: Recent Advances, Challeng...Yoon Sup Choi
I reviewed recent advances, challenges, and opportunities to implement clinical cancer genomics. Case studies of advanced systems, such as Foundation Medicine, MI-ONCOSEQ are introduced for benchmark. A few fundamental limitations to establish personalized oncology are also discussed.
Updated poster following beta v3 release. In preparation for Pharmacology Futures, Edinburgh Immunology Symposium and Word Congress of Pharmacology (Kyoto)
USE OF PET – HEALTH CARE POLICY PERSPECTIVESRuby Med Plus
POSITRON EMISSION TOMOGRAPHY (PET) USE BY TERTIARY HEALTH CARE CENT RES AND ITS ACCESSIBILITY TO POPULATION: A POLICY PERSPECTIVE. a BRIEF Cost-Benefit analysis.
Neuroendocrine tumors are highly angiogenic and angiogenesis represents a major target for therapeutic interventions. Herein, are reviewed recent data on angiogenesis and anti-angiogenic agents in neuroendocrine tumors.
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfDoriaFang
Scientists are turning their attention to more innovative therapeutic strategies, such as next-generation ADCs, bispecific antibodies and CAR-T cell therapies, etc. as cancer therapy.
Similar to Webinar - Imaging technologies to visualise drug discovery (20)
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at overcoming the challenges of scaling up a complex medicine.
Graham Worrall and Emily Port, CPI
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the advantages of good formulation.
Claire Patterson, Seda Pharmaceutical Development Services
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at whether complex medicines raise different challenges from a safety perspective.
Richard Knight (Apconix)
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look Lipid Nanoparticles, and how there is so much more to them than being a little fat blob.
Yvonne Perrie (University of Strathclyde)
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at alternative delivery for mRNA vaccines.
Helen McCarthy, pHion Therapeutics
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the interaction of colloidal gene delivery vehicles with model biomembranes.
Jayne Lawrence, The University of Manchester
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck gives an overview of the early assessment of Prototype Nanomedicine Nano Bio Interactions.
Zahra Rattray, University of Strathclyde
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the challenges of determining drug levels and pk profiles for complex drug modalities.
Robert Wheller, LGC
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life Sciences
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at CryoEM in characterisation and quality control of complex medicines
Dr Rebecca Thompson, Astbury Biostructure Laboratory
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at cellular internalisation and trafficking of complex medicines.
Dr Jamie Szczerkowski, Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at Complex Medicine and articulates what the commercial opportunity could be.
David Cook, Blueberry Therapeutics
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...Studia Poinsotiana
I Introduction
II Subalternation and Theology
III Theology and Dogmatic Declarations
IV The Mixed Principles of Theology
V Virtual Revelation: The Unity of Theology
VI Theology as a Natural Science
VII Theology’s Certitude
VIII Conclusion
Notes
Bibliography
All the contents are fully attributable to the author, Doctor Victor Salas. Should you wish to get this text republished, get in touch with the author or the editorial committee of the Studia Poinsotiana. Insofar as possible, we will be happy to broker your contact.
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...Scintica Instrumentation
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes.
In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
Selecting the right drugs for the right patients, using biomarkers to stratify this and improve predictability of drug response.
Next I will introduce the technologies and show some selected examples before going into multi-modality.
Looking at samples on different scales is one reason ofor implementing multiple imaging techniques. However as you may know, there is a wealth of other information to be gained.
As discussed each of the modalities offer a unique offering – PET and NIR imaging are frequently used to measure and assess compound distribution and accumulation – PET is a functional imaging technique radiolabelled distribution studies can be performed either using direct labelling or indirect approaches – they can be used to assess the distribution of the candidate compounds longitudinally – especially with larger molecules and biologics where there are limited ways to gain quantititvate assessment of distribution – PET is a very sensitive methods and can be done in 3D
Looking at samples on different scales is one reason for implementing multiple imaging techniques. However as you may know, there is a wealth of other information to be gained. In general, the following ex-vivo techniques can be used for assessing biological activity, and toxicity (biomarkers), and in some cases for looking at drug distribution and evidence or target engagement or target validation.
In this particular case these images were generated by Ekta from FFPE tissue where paraffin removal, antigen retrieval and on-tissue, in-situ digestion was carried out. Generally we find fresh frozen tissue to be best due to the harsh treatment required to handle fFPE tissues.
For model characterisation, for drug distribution, for biomarker analysis
For model characterisation, for drug distribution, for biomarker analysis. This work is ongoing and workflows will be applied to other organoid and spheroid models for drug distribution and monitoring of biomarkers for biological activity, evidence of efficacy, toxicity etc.
When increasing the resolution we see that there are many more receptors present in the cell membrane than there appears to be in the lower res images. This allows for better measurement of distance between molecules and for precise imaging of defined structures, such as mitochondria. This is intended to be implemented for target validation and engagement studies.
Looking at samples on different scales is one reason ofor implementing multiple imaging techniques. However as you may know, there is a wealth of other information to be gained.
Can track cells in-vivo, mainly immune, t-cells, b-cells, macrophages. New and noevl ways of labelling them where we don’t currently have any way of doing so at the moment (easily, in-vivo).
We are also looking to further this by taking a similar but unlabelled approach with MSI
In addition to the humanised approach we are aiming for with the organoid and spheroid models in-vitro (mentioned previously), there are a number of ways that we can use preclinical imaging to humanise the drug discovery approach. Using orthotopic models in addition to subcutaneous models
Summary: there are a variety of different approaches that can be used for in-vivo, ex-vivo and in-vitro imaging.